29 research outputs found
Mitochondrial Mutations in Subjects with Psychiatric Disorders
A considerable body of evidence supports the role of mitochondrial dysfunction in psychiatric disorders and mitochondrial DNA (mtDNA) mutations are known to alter brain energy metabolism, neurotransmission, and cause neurodegenerative disorders. Genetic studies focusing on common nuclear genome variants associated with these disorders have produced genome wide significant results but those studies have not directly studied mtDNA variants. The purpose of this study is to investigate, using next generation sequencing, the involvement of mtDNA variation in bipolar disorder, schizophrenia, major depressive disorder, and methamphetamine use. MtDNA extracted from multiple brain regions and blood were sequenced (121 mtDNA samples with an average of 8,800x coverage) and compared to an electronic database containing 26,850 mtDNA genomes. We confirmed novel and rare variants, and confirmed next generation sequencing error hotspots by traditional sequencing and genotyping methods. We observed a significant increase of non-synonymous mutations found in individuals with schizophrenia. Novel and rare non-synonymous mutations were found in psychiatric cases in mtDNA genes: ND6, ATP6, CYTB, and ND2. We also observed mtDNA heteroplasmy in brain at a locus previously associated with schizophrenia (T16519C). Large differences in heteroplasmy levels across brain regions within subjects suggest that somatic mutations accumulate differentially in brain regions. Finally, multiplasmy, a heteroplasmic measure of repeat length, was observed in brain from selective cases at a higher frequency than controls. These results offer support for increased rates of mtDNA substitutions in schizophrenia shown in our prior results. The variable levels of heteroplasmic/multiplasmic somatic mutations that occur in brain may be indicators of genetic instability in mtDNA
Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin
Huntington's disease (HD), a progressive neurodegenerative disease, is caused by an expanded CAG triplet repeat producing a mutant huntingtin protein (mHTT) with a polyglutamine-repeat expansion. Onset of symptoms in mutant huntingtin gene-carrying individuals remains unpredictable. We report that synthetic polyglutamine oligomers and cerebrospinal fluid (CSF) from BACHD transgenic rats and from human HD subjects can seed mutant huntingtin aggregation in a cell model and its cell lysate. Our studies demonstrate that seeding requires the mutant huntingtin template and may reflect an underlying prion-like protein propagation mechanism. Light and cryo-electron microscopy show that synthetic seeds nucleate and enhance mutant huntingtin aggregation. This seeding assay distinguishes HD subjects from healthy and non-HD dementia controls without overlap (blinded samples). Ultimately, this seeding property in HD patient CSF may form the basis of a molecular biomarker assay to monitor HD and evaluate therapies that target mHTT
Supplementary Material for: Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence
<p>Subjects with schizophrenia (SZ) and bipolar disorder (BD) show
decreased protein and transcript levels for mitochondrial complex I. In
vitro results suggest antipsychotic and antidepressant drugs may be
responsible. We measured complex I activity in BD, SZ, and controls and
presence of antipsychotic and antidepressant medications, mitochondrial
DNA (mtDNA) copy number, and the mtDNA “common deletion” in the brain.
Complex I activity in the prefrontal cortex was decreased by 45% in SZ
compared to controls (<i>p</i> = 0.02), while no significant difference was found in BD. Complex I activity was significantly decreased (<i>p</i>
= 0.01) in pooled cases (SZ and BD) that had detectable psychotropic
medications and drugs compared to pooled cases with no detectable
levels. Subjects with age at onset in their teens and psychotropic
medications showed decreased (<i>p</i> < 0.05) complex I activity
compared to subjects with an adult age at onset. Both SZ and BD groups
displayed significant increases (<i>p</i> < 0.05) in mtDNA copy
number compared to controls; however, common deletion burden was not
altered. Complex I deficiency is found in SZ brain tissue, and
psychotropic medications may play a role in mitochondrial dysfunction.
Studies of medication-free first-episode psychosis patients are needed
to elucidate whether mitochondrial pathophysiology occurs independent of
medication effects.</p